Clinical Trial Update: Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study (TALENT) evaluated tislelizumab with anlotinib and XELOX chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Gastric Cancer | Phase 1, Phase 2 | Status: COMPLETED